HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (16)
  • Publications (14)
  • References (21)
  • Uncategorized (6)

Recent Posts

April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio
April 7, 2025

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

by PJWCreative
January 13, 2025

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

by PJWCreative
December 18, 2024

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

by PJWCreative
Post placeholder image
September 18, 2024

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 16, 2024

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
August 8, 2024 in Publications

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

PJWCreative 0 Like Post Comments Off on ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

Click here

Read More
Post placeholder image
June 21, 2024 in Publications

American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys

HighField Bio 0 Like Post Comments Off on American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys

Click here

Read More
Post placeholder image
February 12, 2023 in Publications

Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

PJWCreative 0 Like Post Comments Off on Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

Click here

Read More
Post placeholder image
August 30, 2022 in Publications

mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy

PJWCreative 0 Like Post Comments Off on mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy

Click here

Read More
Post placeholder image
April 12, 2022 in Publications

Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment

PJWCreative 0 Like Post Comments Off on Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment

Click here

Read More
Post placeholder image
January 10, 2022 in Publications

Pharmaceutical Research: Biodistribution and Non-linear Gene Expression of MRNA LNPs Affected by Delivery Route and Particle Size

PJWCreative 0 Like Post Comments Off on Pharmaceutical Research: Biodistribution and Non-linear Gene Expression of MRNA LNPs Affected by Delivery Route and Particle Size

Click here

Read More
Post placeholder image
August 31, 2021 in Publications

Pharmaceutical Research: Surface Ligand Valency and Immunoliposome Binding: When More is Not Always Better

PJWCreative 0 Like Post Comments Off on Pharmaceutical Research: Surface Ligand Valency and Immunoliposome Binding: When More is Not Always Better

Click here

Read More
Post placeholder image
September 9, 2020 in Publications

Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond

PJWCreative 0 Like Post Comments Off on Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond
Read More
Post placeholder image
September 3, 2020 in Publications

When liposomes met antibodies: Drug delivery and beyond

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
March 2, 2020 in Publications

Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging

PJWCreative 0 Like Post Comments Off on Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging
Read More
Prev12Next

Download Company Profile

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin
HIGHfield_logo_horizontal_FINAL_trans

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

HIGHFIELD_web_LI_icon_x75

© 2024 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文